{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:26:59Z","timestamp":1787311619077,"version":"build-2736575974"},"reference-count":58,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Primary sclerosing cholangitis (PSC) is a serious liver disease associated with inflammatory bowel disease (IBD). Galectin-3, an inflammatory and fibrotic molecule, has elevated circulating levels in patients with chronic liver disease and inflammatory bowel disease (IBD). This study aims to clarify whether galectin-3 can differentiate between patients with IBD, PSC, and PSC-IBD. Our study measured serum galectin-3 levels in 38 healthy controls, 55 patients with IBD, and 22 patients with PSC (11 patients had underlying IBD and 11 patients did not), alongside the urinary galectin-3 of these patients and 18 controls. Serum and urinary galectin-3 levels in IBD patients were comparable to those in controls. Among IBD patients, those with high fecal calprotectin, indicating severe disease, exhibited lower serum and elevated urinary galectin-3 levels compared to those with low calprotectin levels. Serum galectin-3 levels were inversely correlated with C-reactive protein levels. PSC patients displayed higher serum and urinary galectin-3 levels than IBD patients, with the highest serum levels observed in PSC patients with coexisting IBD. There was no correlation between serum and urinary galectin-3 levels and laboratory indicators of liver injury in both IBD and PSC patients. In conclusion, this study demonstrates that serum and urinary galectin-3 levels can distinguish IBD from PSC patients, and also reveals higher serum galectin-3 levels in PSC-IBD patients compared to those with isolated PSC.<\/jats:p>","DOI":"10.3390\/ijms25094765","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T08:02:22Z","timestamp":1714723342000},"page":"4765","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Serum Galectin-3 as a Non-Invasive Marker for Primary Sclerosing Cholangitis"],"prefix":"10.3390","volume":"25","author":[{"given":"Ganimete","family":"Bajraktari","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Elger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Huss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Loibl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Albert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9065-8395","authenticated-orcid":false,"given":"Arne","family":"Kandulski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-4568","authenticated-orcid":false,"given":"Martina","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke Christian","family":"Tews","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-3994","authenticated-orcid":false,"given":"Christa","family":"Buechler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e7116","DOI":"10.1097\/MD.0000000000007116","article-title":"Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom","volume":"96","author":"Liang","year":"2017","journal-title":"Medicine"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1053\/j.sult.2022.06.007","article-title":"Practical Guide for Radiological Diagnosis of Primary and Secondary Sclerosing Cholangitis","volume":"43","author":"Pria","year":"2022","journal-title":"Semin. Ultrasound CT MR"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.29293","article-title":"Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group","volume":"66","author":"Schramm","year":"2017","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1148\/radiol.10091953","article-title":"Primary sclerosing cholangitis: Meta-analysis of diagnostic performance of MR cholangiopancreatography","volume":"256","author":"Dave","year":"2010","journal-title":"Radiology"},{"key":"ref_5","first-page":"124","article-title":"Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: An update of the evidence","volume":"32","author":"Mertz","year":"2019","journal-title":"Ann. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/j.1572-0241.2007.01343.x","article-title":"The immune response in inflammatory bowel disease","volume":"102","author":"Brown","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.disamonth.2017.07.001","article-title":"A comprehensive review and update on Crohn\u2019s disease","volume":"64","author":"Gajendran","year":"2018","journal-title":"Dis. Mon."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis. Mon."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","article-title":"Immunological pathogenesis of inflammatory bowel disease","volume":"16","author":"Lee","year":"2018","journal-title":"Intest. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"914505","DOI":"10.3389\/fmmed.2022.914505","article-title":"A Review on Biomarkers for the Evaluation of Autoimmune Cholestatic Liver Diseases and Their Overlap Syndromes","volume":"2","author":"Nguyen","year":"2022","journal-title":"Front. Mol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.pathol.2019.07.002","article-title":"The significance of ANCA positivity in patients with inflammatory bowel disease","volume":"51","author":"Lee","year":"2019","journal-title":"Pathology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/apt.16153","article-title":"Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): Antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis","volume":"53","author":"Wunsch","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_13","first-page":"599","article-title":"Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)","volume":"41","author":"Dong","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cyto.2014.06.016","article-title":"Free fatty acids and IL-6 induce adipocyte galectin-3 which is increased in white and brown adipose tissues of obese mice","volume":"69","author":"Krautbauer","year":"2014","journal-title":"Cytokine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1210\/jc.2009-1619","article-title":"Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes","volume":"95","author":"Weigert","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6661937","DOI":"10.1155\/2021\/6661937","article-title":"6-Gingerol, a Major Ingredient of Ginger Attenuates Diethylnitrosamine-Induced Liver Injury in Rats through the Modulation of Oxidative Stress and Anti-Inflammatory Activity","volume":"2021","author":"Alsahli","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wang, W., Gao, W., Zhu, Q., Alasbahi, A., Seki, E., and Yang, L. (2021). TAK1: A Molecular Link Between Liver Inflammation, Fibrosis, Steatosis, and Carcinogenesis. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.734749"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2119\/molmed.2014.00178","article-title":"Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis","volume":"21","author":"Jeftic","year":"2015","journal-title":"Mol. Med."},{"key":"ref_20","first-page":"669","article-title":"Galectin-3 Concentration in Liver Diseases","volume":"45","author":"Gudowska","year":"2015","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cyto.2011.06.001","article-title":"Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function","volume":"55","author":"Wanninger","year":"2011","journal-title":"Cytokine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.0.CO;2-0","article-title":"Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma","volume":"81","author":"Hsu","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1111\/liv.15326","article-title":"Galectin-3 is overexpressed in advanced cirrhosis and predicts post-liver transplant infectious complications","volume":"42","author":"Vilatoba","year":"2022","journal-title":"Liver Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8831","DOI":"10.3748\/wjg.v19.i47.8831","article-title":"Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma","volume":"19","author":"Bacigalupo","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"744518","DOI":"10.3389\/fmed.2021.744518","article-title":"Role of Galectins in the Liver Diseases: A Systematic Review and Meta-Analysis","volume":"8","author":"An","year":"2021","journal-title":"Front. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/jcp.2005.032391","article-title":"Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease","volume":"60","author":"Butscheid","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/hupa.2001.22767","article-title":"Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma","volume":"32","author":"Shimonishi","year":"2001","journal-title":"Hum. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Slack, R.J., Mills, R., and Mackinnon, A.C. (2021). The therapeutic potential of galectin-3 inhibition in fibrotic disease. Int. J. Biochem. Cell Biol., 130.","DOI":"10.1016\/j.biocel.2020.105881"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.krcp.2012.04.322","article-title":"TGF-beta-activated kinase-1: New insights into the mechanism of TGF-beta signaling and kidney disease","volume":"31","author":"Kim","year":"2012","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Yang, C., and Merlin, D. (2024). Unveiling Colitis: A Journey through the Dextran Sodium Sulfate-induced Model. Inflamm. Bowel Dis., izad312.","DOI":"10.1093\/ibd\/izad312"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Volarevic, V., Zdravkovic, N., Harrell, C.R., Arsenijevic, N., Fellabaum, C., Djonov, V., Lukic, M.L., and Simovic Markovic, B. (2019). Galectin-3 Regulates Indoleamine-2,3-dioxygenase-Dependent Cross-Talk between Colon-Infiltrating Dendritic Cells and T Regulatory Cells and May Represent a Valuable Biomarker for Monitoring the Progression of Ulcerative Colitis. Cells, 8.","DOI":"10.3390\/cells8070709"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000431312","article-title":"Galectin-3 Modulates Experimental Colitis","volume":"92","author":"Lippert","year":"2015","journal-title":"Digestion"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00011-009-0016-8","article-title":"Detection of galectin-3 in patients with inflammatory bowel diseases: New serum marker of active forms of IBD?","volume":"58","author":"Smetana","year":"2009","journal-title":"Inflamm. Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Yu, T.B., Dodd, S., Yu, L.G., and Subramanian, S. (2020). Serum galectins as potential biomarkers of inflammatory bowel diseases. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0227306"},{"key":"ref_35","first-page":"95","article-title":"Serum galectin 3, galectin 9 and galectin 3-binding proteins in patients with active and inactive inflammatory bowel disease","volume":"70","author":"Cibor","year":"2019","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Tews, H.C., Elger, T., Grewal, T., Weidlich, S., Vitali, F., and Buechler, C. (2023). Fecal and Urinary Adipokines as Disease Biomarkers. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041186"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.cardfail.2017.07.084","article-title":"Urine Galectin-3 Levels Identify High Risk Renal Dysfunction in Patients with Heart Failure","volume":"23","author":"Ahmad","year":"2017","journal-title":"J. Card. Fail."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00432-008-0481-4","article-title":"Galectin-3 in urine of cancer patients: Stage and tissue specificity","volume":"135","author":"Balasubramanian","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.rdc.2018.06.007","article-title":"Renal Manifestations of Inflammatory Bowel Disease","volume":"44","author":"Ambruzs","year":"2018","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e936497","DOI":"10.12659\/MSM.936497","article-title":"Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic Era","volume":"28","author":"Dincer","year":"2022","journal-title":"Med. Sci. Monit."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jceh.2018.01.004","article-title":"Prevalence of Nephrolithiasis in Patients with Chronic Liver Disease: A Case-Control Study","volume":"8","author":"Porter","year":"2018","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/10408363.2020.1723487","article-title":"Diagnostic utility of protein to creatinine ratio (P\/C ratio) in spot urine sample within routine clinical practice","volume":"57","author":"Kaminska","year":"2020","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Hara, A., Niwa, M., Noguchi, K., Kanayama, T., Niwa, A., Matsuo, M., Hatano, Y., and Tomita, H. (2020). Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules, 10.","DOI":"10.3390\/biom10030389"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/mi.2017.107","article-title":"Epithelial-mesenchymal transition in Crohn\u2019s disease","volume":"11","author":"Jiang","year":"2018","journal-title":"Mucosal Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00109-015-1368-x","article-title":"Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis","volume":"94","author":"Tsai","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/tgh-20-266","article-title":"Primary sclerosing cholangitis","volume":"6","author":"Rabiee","year":"2021","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/hep.30319","article-title":"Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis","volume":"70","author":"Banales","year":"2019","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.3748\/wjg.v25.i43.6465","article-title":"Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression","volume":"25","author":"Jovanovic","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Rennebaum, F., Demmig, C., Schmidt, H.H., Vollenberg, R., Tepasse, P.R., Trebicka, J., Gu, W., Ullerich, H., Kabar, I., and Cordes, F. (2023). Elevated Liver Fibrosis Progression in Isolated PSC Patients and Increased Malignancy Risk in a PSC-IBD Cohort: A Retrospective Study. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242015431"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"105067","DOI":"10.1016\/j.archger.2023.105067","article-title":"Multimorbidity patterns in the German general population aged 40 years and over","volume":"114","author":"Amirzada","year":"2023","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.amjmed.2022.08.012","article-title":"Inflammatory Bowel Disease and Cardiovascular Diseases","volume":"135","author":"Chen","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2796.2011.02476.x","article-title":"The fibrosis marker galectin-3 and outcome in the general population","volume":"272","author":"Gansevoort","year":"2012","journal-title":"J. Intern. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"P4243","DOI":"10.1093\/eurheartj\/eht309.P4243","article-title":"Urinary and plasma galectin-3 in heart failure\u2014Insights in renal handling","volume":"34","author":"Meijers","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1055\/a-1015-7048","article-title":"Aktualisierung der S3-Leitlinie Colitis ulcerosa 2019","volume":"57","author":"Kucharzik","year":"2019","journal-title":"Z. Gastroenterol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects","volume":"13","author":"Sturm","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"(2022). EASL Clinical Practice Guidelines on sclerosing cholangitis. J. Hepatol., 77, 761\u2013806.","DOI":"10.1016\/j.jhep.2022.05.011"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.3748\/wjg.v28.i21.2291","article-title":"Serological biomarkers for management of primary sclerosing cholangitis","volume":"28","author":"Tornai","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00261-022-03655-6","article-title":"Primary sclerosing cholangitis: Review for radiologists","volume":"48","author":"Morgan","year":"2023","journal-title":"Abdom. Radiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4765\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:34:28Z","timestamp":1760106868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":58,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25094765"],"URL":"https:\/\/doi.org\/10.3390\/ijms25094765","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,27]]}}}